News

News Releases

Recent news releases

Month Year

Month Year

Investor Alerts

May 26, 2026

Apotex expands ophthalmic portfolio with Health Canada approval of IHEEZO™
May 14, 2026

Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
May 1, 2026

Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
Apr 23, 2026

Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
Apr 7, 2026

Apotex Strengthens Osteoporosis Care in Canada with Health Canada's Approval of DENOZA™, a Denosumab Biosimilar

Show per page